Sangamo Therapeutics Current Valuation vs. Price To Sales

SGMO Stock  USD 1.94  0.21  9.77%   
Based on Sangamo Therapeutics' profitability indicators, Sangamo Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Sangamo Therapeutics' ability to earn profits and add value for shareholders. As of the 5th of December 2024, Price To Sales Ratio is likely to drop to 0.51. In addition to that, Days Sales Outstanding is likely to drop to 2.61. At this time, Sangamo Therapeutics' Total Other Income Expense Net is very stable compared to the past year. As of the 5th of December 2024, Non Operating Income Net Other is likely to grow to about 11.4 M, though Accumulated Other Comprehensive Income is likely to grow to (4.4 M).
For Sangamo Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sangamo Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sangamo Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sangamo Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sangamo Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.24)
Revenue Per Share
0.066
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.58)
Return On Equity
(1.94)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sangamo Therapeutics Price To Sales vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sangamo Therapeutics's current stock value. Our valuation model uses many indicators to compare Sangamo Therapeutics value to that of its competitors to determine the firm's financial worth.
Sangamo Therapeutics is rated fourth in current valuation category among its peers. It also is rated fourth in price to sales category among its peers . The ratio of Current Valuation to Price To Sales for Sangamo Therapeutics is about  56,469,198 . At this time, Sangamo Therapeutics' Price To Sales Ratio is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sangamo Therapeutics' earnings, one of the primary drivers of an investment's value.

Sangamo Current Valuation vs. Competition

Sangamo Therapeutics is rated fourth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 40.87 Billion. Sangamo Therapeutics claims roughly 437.12 Million in current valuation contributing just under 2% to equities under Health Care industry.

Sangamo Price To Sales vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Sangamo Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
437.12 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Sangamo Therapeutics

P/S

 = 

MV Per Share

Revenue Per Share

 = 
7.74 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Sangamo Price To Sales Comparison

Sangamo Therapeutics is currently under evaluation in price to sales category among its peers.

Sangamo Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sangamo Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sangamo Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Sangamo Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Sangamo Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4.6 M-4.4 M
Operating Income-274 M-260.3 M
Net Loss-257.8 M-244.9 M
Income Tax Expense-5.1 M-4.8 M
Income Before Tax-262.9 M-249.8 M
Total Other Income Expense Net11.1 M11.7 M
Net Loss-249.5 M-237 M
Non Operating Income Net Other10.8 M11.4 M
Net Loss-173.1 M-164.4 M
Interest Income13.3 M7.1 M
Net Interest Income13.3 M7.9 M
Change To Netincome36.4 M38.2 M
Net Loss(1.48)(1.55)
Income Quality 0.87  0.92 
Net Income Per E B T 0.98  0.77 

Sangamo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sangamo Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sangamo Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sangamo Therapeutics' important profitability drivers and their relationship over time.

Use Sangamo Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Sangamo Therapeutics Pair Trading

Sangamo Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sangamo Therapeutics position

In addition to having Sangamo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Disruptive Technologies Thematic Idea Now

Disruptive Technologies
Disruptive Technologies Theme
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out World Market Map.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
To fully project Sangamo Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sangamo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sangamo Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Sangamo Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Sangamo Therapeutics investors may work on each financial statement separately, they are all related. The changes in Sangamo Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sangamo Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.